Our candidate Optimer therapeutics provide new opportunities to control and modify diseases. We continue to strive to address the unmet needs of patients who have limited or inadequate treatment options.
Therapeutic Development Partners
We have a partnership-based business model as we generate and combine Optimers for our partners on a target by target basis. Optimer-based biotherapeutics are currently being developed in collaboration with Astra Zeneca, Cancer Research UK and other undisclosed partners.
We are looking for new partners for custom generation and combinations of Optimers as next-generation biopharmaceuticals.
Cancer Research UK
Aptamer Group has established a collaboration with Cancer Research UK and Dan Wiseman and the Oglesby Leukaemia Research Programme at the University of Manchester. The project will explore the potential of aptamers as therapeutic agents for the treatment of Chronic Myelomonocytic Leukaemia (CMML) and other myeloid malignancies. The partnership intends to build on initial data showing the therapeutic potential of aptamers that can selectively target a key genetic mechanism involved in driving this group of cancers.
Aptamer Group have established a collaboration with AstraZeneca to explore the potential of using aptamer technology to target the kidney. The two-year agreement will give AstraZeneca use of Aptamer Group’s proprietary technology to explore the feasibility of developing the next generation drug delivery vehicles, as Optimer-drug conjugates.
This collaborative project, which brings together the platform technology developed at Aptamer Group and AstraZeneca’s leadership in Cardiovascular, Renal and Metabolism (CVRM) therapy development and expertise in drug discovery and development, aims to use Optimer-drug conjugates to enable targeted delivery specifically to the kidney.